[(5,6,9a-substituted-3-oxo-1,2,9,9a-tet rahydro-3H-fluoren-7-yl)oxy]alkanoic and cycloalkanoic acid esters and their analogs, the parent acids and their salts
AssigneeMerck & Co., Inc.
InventorsEdward J. Cragoe, Jr., Gerald E. Stokker, Norman P. Gould
Life of this patent
Estimating the term…
Abstract
The invention relates to novel [(5,6,9a-substituted-3-oxo-1,2,9,9a-tetrahydro-3H-fluoren-7-yl)oxy]alkanoi c and cycloalkanoic acids and their analogs, esters, salts and derivatives. These compounds are synthesized by methods selected from a number of synthetic routes depending on the particular structure, choice of intermediate or preferred reaction sequence. The compounds are useful in the treatment and prevention of injury to the brain and spinal chord due to accidents, ischemic stroke and hydrocephalus; compositions for such uses are also disclosed.
Claims16
A compound of the formula:
- ##STR21## wherein R is C.sub.3 to C.sub.6 cycloalkyl and C.sub.3 to C.sub.6 cycloalkyl C.sub.1 to C.sub.4 alkyl, branched or unbranched;
- R.sup.1 is H, lower alkyl;
- lower alkenyl;
- lower alkynyl;
- lower cycloalkyl;
- substituted lower alkyl, where the substituent is carboxy, lower alkoxycarbonyl, oxo, hydroxy, lower alkoxy, halo, lower acyloxy, lower dialkylamino, sulfamoyl, pyridyl, furyl, tetrahydrofuryl, aryl, 1-methylpiperidyl, morpholinyl, pyrrolidinyl, 1-methylpiperazinyl, and thienyl;
- substituted cycloalkyl;
- a heterocyclic moiety selected from the group consisting of imidazolyl, pyridyl, thiazolyl, pyrazinyl, and furyl;
- aryl;
- Y.sup.1 and Y.sup.2 are independently Cl and CH.sub.3 ;
- A is (CH.sub.2).sub.2 or ##STR22## where R.sup.2 is H, methyl or ethyl, R.sup.3 is H, F or methyl and R.sup.2 and R.sup.3, may be joined together to form the ring >C(CH.sub.2).sub.n where n is the integer 2, 3, or 4;
- and pharmaceutically acceptable salts thereof.
A compound which is the (+) enantiomer of [(5,6-dichloro-9a-cyclopropyl-3-oxo-1,2,9,9a-tetrahydro-3H-fluoren-7-yl)ox y]acetic acid.
A compound which is the (+) enantiomer of [(5,6-dichloro-9a-cyclopropylmethyl-3-oxo-1,2,9,9a-tetrahydro-3H-fluoren-7 -yl)oxy]acetic acid.
A compound which is the (+) enantiomer of 1-carboxyl-1-methylethyl [(5,6-dichloro-9a-cyclopropyl-3-oxo-1,2,9,9a-tetrahydro-3H-fluoren-7-yl)ox y]acetate.
A compound which is the (+) enantiomer of 1-carboxyl-1-methylethyl [(5,6-dichloro-9a-cyclopropylmethyl-3-oxo-1,2,9,9a-tetrahydro-3H-fluoren-7 -yl)oxy]acetate.
A composition in unit dosage form for the treatment of grey matter edema comprising a compound of the formula:
- ##STR24## wherein R is C.sub.3 to C.sub.6 cycloalkyl and C.sub.3 to C.sub.6 cycloalkyl C.sub.1 to C.sub.4 alkyl;
- R.sup.1 is H, lower alkyl;
- lower alkenyl;
- lower alkynyl;
- lower cycloalkyl;
- substituted lower alkyl, where the substitutent is carboxy, lower alkoxycarbonyl, oxo, hydroxy, lower alkoxy, halo, lower acyloxy, lower dialkylamino, sulfamoyl, pyridyl, furyl, tetrahydrofuryl, aryl, 1-methylpiperidyl, morpholinyl, pyrrolidinyl, 1-methylpiperazinyl, and thienyl;
- substituted cycloalkyl;
- a heterocyclic moiety selected from the group consisting of imidazolyl, pyridyl, thiazolyl, pyrazinyl, and furyl;
- aryl;
- Y.sup.1 and Y.sup.2 are independently Cl and CH.sub.3 ;
- A is (CH.sub.2).sub.2 or ##STR25## where R.sup.2 is H, methyl or ethyl, R.sup.3 is H, F or methyl and R.sup.2 and R.sup.3, may be joined together to form the ring >C(CH.sub.2) where n is the integer 2, 3 or 4;
- and pharmaceutically acceptable salts thereof.
Dependencies are inferred from the claim text.